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The occurrence of 20 human pharmaceutical compounds and metabolites from 10 representative
therapeutic classes was analysed from resource and drinking water in two catchment basins located in
north-west France. 98 samples were analysed from 63 stations (surface water and drinking water
produced from surface water). Of the 20 human pharmaceutical compounds selected, 16 were
quantified in both the surface water and drinking water, with 22% of the values above the limit of
quantification for surface water and 14% for drinking water). Psychostimulants, non-steroidal anti-
inflammatory drugs, iodinated contrast media and anxiolytic drugs were the main therapeutic classes of
human pharmaceutical compounds detected in the surface water and drinking water. The results for
surface water were close to results from previous studies in spite of differences in prescription rates of
human pharmaceutical compounds in different countries. The removal rate of human pharmaceutical
compounds at 11 water treatment units was also determined. Only caffeine proved to be resistant to
drinking water treatment processes (with a minimum rate of 5%). Other human pharmaceutical
compounds seemed to be removed more efficiently (average elimination rate of over 50%) by
adsorption onto activated carbon and oxidation/disinfection with ozone or chlorine (not taking
account of the disinfection by-products). These results add to the increasing evidence of the occurrence
of human pharmaceutical compounds in drinking water that may represent a threat to human beings
exposed to a cocktail of human pharmaceutical compounds and related metabolites and by-products in
drinking water.
Introduction
Human pharmaceutical compounds (HPCs) are emerging
contaminants as their discharge are not (yet) regulated. They are
continuously entering the aquatic environment, directly through
treated wastewater (TWW) discharge or indirectly by landfill
leachates. HPCs are bioactive compounds originally designed
and prescribed to have a specific biological effect on the human
body. Depending on their metabolization, HPCs are excreted
from the human body as parent compounds and/or metabolites
in urine and/or faeces. Wastewater (WW) treatment is the
primary attenuation stage1,2 but natural attenuation of HPCs
may occur in surface water (SW), by i) dilution of TWW effluents
(concentrations measured in mg L1) in natural water (concen-
trations measured in ng L1), ii) adsorption onto natural organic
matter (suspended matter, colloids, dissolved organic matter)
and iii) other reactions such as phototransformation and
biodegradation. Nevertheless, many studies have shown the
presence of HPCs in natural waters at concentrations of the
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Environmental impact
Pharmaceutical compounds in the drinking water cycle may represent a potential threat to human beings as a few works have
demonstrated their effects in mixture on human health. In this study, the occurrence of 20 human pharmaceutical compounds was
determined in surface and drinking water in north-west France and their qualitative and quantitative distribution was studied. Their
removal rate through 11 water utilities is also discussed. Considering the scarcity of data related to the contamination of human
pharmaceutical compounds in drinking water this study provides data for the human health risk assessment related to these
substances.
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order of mg L1 3–14 and a few reported HPCs in drinking water
(DW) of the order of ng L1.8,15
However, in some areas where surface water is the main source
of DW, such as Brittany (north-west France) where 80% of DW
is taken from SW, controlling HPCs in DW may be an
unavoidable issue for human health risk.16 Although DW treat-
ment processes were not originally designed to remove phar-
maceutical contamination from DW supplies, removing HPCs
could become a necessity.17,18
The aim of this study was to determine the occurrence of 20
HPCs andmetabolites in SWandDW in two catchments basins in
north-west France. It may also provide an insight as to the urban
impact and monthly variations in HPCs concentrations in SW
besides a greater understanding of the efficiency of existing DW
treatment processes to remove HPCs from contaminated SW.
Materials and methods
Selection of target compounds
A prioritization approach was proposed for selecting HPCs to be
analysed from all those prescribed (around 3000 in France for
example). A list of 20 HPCs and metabolites from 10 represen-
tative classes (Table 1) was drawn up using the following criteria:
i) Widespread use for human medication in France in terms of
therapeutic practices and quantities consumed33–35 and the existence
of several studies reporting their occurrence in water (Table 1).
ii) HPCs poorly metabolized in the human body or having
metabolites known to be weakly biodegradable and physically
and chemically stable in the environment.8
iii) Suspected toxicity of HPCs or their metabolites (e.g. anti-
neoplastic known for their non-threshold cytotoxic activity).8,36,37
iv) Existing standards and analytical feasibility.
Study area and sample collection
Sampling was carried out in two catchment basins, the Vilaine
(length ¼ 218 km, catchment basin area ¼ 10 533 km2) and the
Mayenne (length ¼ 202 km, catchment basin area ¼ 4358 km2),
together with their tributaries (Fig. 1). The average discharge of
the Vilaine and the Mayenne is around 70 m3 s1 and 50 m3 s1,
respectively. 70% of the DW in the Ille et Vilaine department is
taken from SW. The Mayenne river supplies 58% of the DW in
the Mayenne basin.
Samples were taken from 63 stations between January and
April 2009. Fig. 1 shows the 31 SW sampling stations (including
SW stations and SW from the inlets of some water utility
stations) and 43 DW sampling stations (DW samples collected at
the outlet of water utility stations).
For some sampling stations, both SW and DW were sampled,
giving a total of 98 samples analysed. Depending on the station,
SW was sampled from the river, the river bank, a bridge, or
a boat. 500 mL of water was collected using a long handled ladle.
For DW, 500 mL was collected directly at the water treatment
plant outlet from the sampling tap connected to the distribution
network. Samples were stored into amber glass bottles and
transported in an icebox at 5 C  3 C, and analysed within
a maximum of 2 days.
Reactants
All HPCs standards had 97% to 99.9% purity and were purchased
from Sigma-Aldrich (Saint Quentin Fallavier, France) except for
IOPwhichwas purchased fromCluzeau InfoLabo (SainteFoyLa
Grande, France). A 1 g L1 stock solution of each HPC was
prepared in HPLC grade methanol and stored at 18 C for use
within 6 months. HPLC grade formic acid (FA) and 98% pure
ammonium hydroxide were purchased from Carlo Erba (Val de
Reuil France) and Fisher Bioblock (Illkirch, France), respec-
tively. HPLC grade acetonitrile (ACN) for ultra performance
liquid chromatography (UPLC) was purchased from J.T Baker
(Atlantic Labo ICS, Bruges, France). A 99% pure standard
pesticide (fenuron), used as a tracer to monitor the progress of
extraction, was purchased from VWR (Fontenay sous Bois,
France). A stock solution of fenuron at 10mgL1was prepared in
methanol and stored at low temperature (+4 C). Purified water
was produced using a Milli-Q water system (Millipore, France)
Table 1 Target HPCs found in drinking water worldwide (see references)
Molecule name CAS number Molecule abbreviation Therapeutic use Refs
Ciprofloxacin 85721-33-1 CIP Antibiotic 19
Flumequine 42935-25-6 FMQ —
Norfloxacin 70458-96-7 NOR 19
Ofloxacin 82419-36-1 OFL 19
Sulfamethoxazole 723-46-6 SFMZ 20,21
Trimethoprim 738-70-5 TRP 19–21
Warfarin 81-81-2 WAR Anticoagulant —
Carbamazepine 298-46-4 CBZ Anticonvulsant 9,17,20–24
Oxazepam 604-75-1 OZP Anxiolytic 21
Cyclophosphamide 6055-19-2 CYCL Antineoplastic —
Atenolol 29122-68-7 ATE b-blocker 20,21
Iopromide 73334-07-3 IOP Iodinated contrast media 25
Clofibric Acid 882-09-7 CLO Lipid regulator 22,26–30
Acetaminophen 103-90-2 ACE Non-steroidal anti-inflammatory drug (NSAID) and analgesic 21,24
Ibuprofen 15687-27-1 IBU 19,21,24,29,31,32
Salicylic Acid 69-72-7 SA 19,21
Codeine 76-57-3 COD Opioid analgesic 9
Morphine 6211-15-0 MRP —
1,7-Dimethylxanthine 611-59-6 DMX Psychostimulant —
Caffeine 58-08-2 CAF 17,24
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and was used during the chromatographic separation as a solvent
in the mobile phase. Mineral water (in a glass bottle – Evian,
Cachat source-SAEME, France), was used for calibration and as
a blank because of its very stable quality and its medium miner-
alization (dry residue at 180 C ¼ 309 mg L1).
Sample preparation
120 mL of 20 g L1 sodium nitrite solution was added to the
samples immediately upon receipt at the laboratory in order to
reduce residual free chlorine. Each homogenized sample
(500 mL) was vacuum-filtered using a 0.7 mm glass fiber filter
because this study was only focused on the presence of HPCs in
the dissolved phase of waters used to produce DW. In order to
optimize the solid phase extraction (SPE) step, the pH was
adjusted to 7 using a pure solution of formic acid or ammonium
hydroxide. 25 mL of fenuron at 10 mg L1 was added before
extraction. The extraction and analytical procedures were
adapted from Tamtam et al.38 A single extraction–separation–
detection procedure was developed for the analysis of the
20 HPCs in SW and DW.
The SPE procedure is widely used for HPCs extraction because
it allows efficient extraction of all compounds, whether alkaline
or acid, for analysis at concentrations in the order of ng L1 in
environmental water samples.39 Oasis hydrophilic–lipophilic
balance (HLB) extraction cartridges (200 mg, 6 mL, Waters,
Saint-Quentin en Yvelines, France) were used to extract from
a 500 mL sample. SPE of HPCs was performed using an ASPEC
XL (automated sample preparation with extraction columns,
Gilson, Villiers-le-Bel, France). Samples were passed through
cartridges previously pre-conditioned with 1 mL of methanol
followed by 1 mL of ultra pure water at a flow rate of 10 mL
min1. HPCs were then eluted with 5 mL of methanol after
washing the cartridges with 2 mL of 5% methanol in ultra pure
water at 2mL min1, and vacuum-dried for 10 min under
nitrogen gas to remove excess water. The extracts were stored in
methanol in a glass tube, at 4 C for a maximum of 2 weeks.
Samples were evaporated under a gentle nitrogen stream until
close to dryness and reconstituted with an acidified (0.01% FA)
5% solution of ACN in water to a volume of 0.5 mL, i.e. an
enrichment factor of 1000, and then transferred into screw cap
vials with silicone–PTFE (polytetrafluoroethylene) septa from
Waters.
UPLC-MS/MS analysis
Using UPLC for analysis provides good sensitivity and reso-
lution within a short analysis time.7,38,40–42 UPLC analysis was
performed using a Waters Acquity UPLC system (Waters,
St-Quentin-en-Yvelines, France), fitted with a binary gradient
module, an autosampler regulated at +4 C, and a column oven
kept at +50 C. The 20 HPCs were separated using an Acquity
UPLC BEH column (1.7 mm particle size, 100  2.1 mm i.d.,
Waters) at a flow rate of 0.5 mL min1. All HPCs were separated
in one single gradient run (15 min) using a binary mobile phase.
10 mL of the final extract sample in 5% acetonitrile in water was
injected. The mobile phase consisted of an ultrapure water–ACN
gradient both acidified with 0.01% FA. The concentration of
Fig. 1 Sampling stations (SW samples were taken from surface water stations and from some water utilities. DW samples were taken from the outlet of
water utilities).
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ACN was held at 5% for the first 3 min, with a linear gradient to
30% from 3–9 min, a linear gradient to 95% from 9–10 min, held
at 95% from 10–12 min and a linear gradient to 5% from 12–
13 min (return to initial conditions), held at 5% from 13–15 min,
(re-equilibration time). The retention times for the analytes are
listed in Table 2.
The UPLC system was coupled to a Quattro Micro triple
quadrupole mass spectrometer (Waters, St-Quentin-en-Yvelines,
France) with an electrospray ionisation (ESI) source with an
orthogonal Z-spray. HPCs were detected by selected reaction
monitoring (SRM) used in positive or negative mode to obtain
the best signal for each HPC (see Table 2). Two SRM-transitions
(m/z, mass to charge ratio) were monitored for each HPC (Table
2), except for IBUwhich has only onem/z transition, with a dwell
time set of 5 ms and a time delay of 2 ms. To achieve the highest
sensitivity, 7 windows containing between one and six analytes
were defined within the 15 min run analysis. Collision energy
(eV), and cone voltage (V) are given in Table 2. The ESI and
desolvation temperatures were 130 C and 450 C respectively.
The capillary voltage was 3 kV. The collision gas (argon) was set
to 2.5 103 mbar (99.9% purity, Air Liquide, Paris, France).
Nitrogen was used as the cone gas at 50 L h1 and desolvation gas
at 650 L h1 (>99.9% purity, Air Liquide). Mass Lynx V4.1 was
used for system control and data processing.
Validation of the analytical protocol
Precautions were taken to provide satisfactory quality assurance.
One blank (mineral water with tracer) was run for each set of
extractions. When the concentrations measured in a blank
exceeded 10% of the concentrations measured for the following
field samples, the results were eliminated. Calibration curves
were obtained by analysing spiked samples. Samples of Evian
mineral water were spiked with a standard solution of all
the HPCs in methanol at 5 different levels of concentration from
5/10ng L1 to 500 ng L1.
Each analyte was identified by i) the retention time compared
to a calibration standard and ii) the presence of the 2 SRM
transitions with a signal to noise ratio (S/N) greater than 3.
In addition, an extraction control of 500 mL of Evian water
spiked with all HPCs at 100 ng L1 was run every 15 samples to
check the extraction step efficiency. The recoveries (%) for each
HPCs (see ESI†) were evaluated for at least 3 replicates in order
to have significant results.
When quantification of a HPC presented a difference greater
than 20% between its two SRM transitions, fenuron was also
used to correct concentration of concerned HPC. In some cases,
when matrix effects were suspected the sample extracts were also
diluted to reduce the impact the impact of ionization on quan-
tification. However, standard addition or the use of an isotope-
labelled internal standard for each target analyte would ideally
be more convenient to avoid the impact of the matrix effect on
the quantitative results. A quadratic regression analysis was used
to estimate concentrations of HPCs in samples (5 calibration
points). Note that for a range from 5 to 200 ng L1 a linear
regression calibration curve can be used for quantification. All
coefficients of correlation (R2) were equal to or greater than 0.95.
Two SRM transitions were considered for HPCs quantification
except for Ibruprofen for which only one m/z transition was
considered for both its identification and quantification. All
positive signals were quantified only when S/N was greater than
or equal to 5 in each sample according to USFDA guidelines.43
The limits of detection (LOD) ranged from 0.3 to 9 ng L1 and
the limits of quantification (LOQ) from 1 to 50 ng L1 (see ESI†).
Table 2 UPLC/MS/MS parameters for target HPC
Abbreviation
Retention time
(min)
Precursor ion
(m/z)
Product ions SRM 1/SRM2
(m/z)
Collision energy
(eV) SRM 1/SRM 2
Cone voltage
(V)
Window 1: 0.0 to 3.5 min [ESI (+)]
MRP 0.9 286.0 165.2/201.2 37/26 44
ACE 1.4 151.9 92.9/110.0 24/16 26
ATE 1.5 267.1 145.0/190.0 24/19 28
DMX 1.8 181.2 68.9/124.0 30/20 30
IOP 2.2 791.0 573.0/300.1 66/32 31
COD 2.4 300.3 215.2/199.1 33/27 43
Window 2: 4.0 to 6.0 min [ESI ()]
SA 5.4 136.8 64.9/92.9 27/15 27
Window 3: 3.5 to 4.2 min [ESI (+)]
CAF 3.8 194.9 138.0/110.0 20/20 34
Window 4: 4.2 to 6.3 min [ESI (+)]
TRP 4.8 291.0 230.2/261.2 24/26 34
NOR 5.3 320.2 233.1/276.2 25/18 29
OFL 5.3 362.0 261.1/318.4 27/20 30
CIP 5.5 332.1 288.4/314.2 18/19 32
Window 5: 6.0 to 9.0 min [ESI (+)]
SFMZ 6.3 254.0 91.8/155.9 27/2 25
CYCL 7.6 261.0 140.0/106.0 18/24 29
Window 6: 8.5 to 15.0 min [ESI (+)]
FMQ 9.4 262.0 202.0/244.0 34/18 24
CBZ 9.6 236.9 192.1/194.1 23/21 30
OZP 9.9 287.0 241.0/269.0 22/15 24
WAR 10.3 309.2 163.0/251.0 15/20 20
Window 7: 8.5 to 15.0 min [ESI ()]
CLO 10.1 213.0 84.9/127.0 10/13 14
IBU 10.4 205.0 161.10/– 8/– 20
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Intra-laboratory reproducibility tests yielded a relative standard
deviation (RSD) of up to 27% in resource water (n ¼ 30) and up
to 15% in DW (n ¼ 25). The evaluation of the inter-laboratory
performances for the analysis of 4 HPCs, i.e. CBZ, OFL, ATE
and ACE, was evaluated during an interlaboratory essay
involving 30 laboratories. The individual absolute z-score were
calculated (according to IUPAC following AOAC and ISO
directives) and were comprised between 0 and 1 for all results
obtained, showing satisfactory performance of the HPCs
analysis method.
Results
The results are given in the ESI.† Taking into account the missing
data owing to experimental errors during sampling or analytical
problems (non validated results), 31% (604) of the 1960 expected
values (98 samples  20 HPCs) were eliminated. Of the validated
results, 68% (920) had concentrations below the LOD, 10% (138)
were between the LOD and the LOQ, and 22% (294) had
concentrations above the LOQ (S/N ratio greater than 5 for each
sample). There was clearly a difference between the SW and DW
samples with 86% of the results (252) above the LOQ for the SW
against 14% (42) for the DW samples.
Concentration distribution
Fig. 2a and 2b show the HPCs concentrations distribution for
SW and DW samples. The range of HPCs concentrations in SW
(Fig. 2a), gives three groups of compounds:
– Compounds with high concentrations in SW (ACE, CAF,
IOP, CLO, DMX, in decreasing order) up to 300 ng L1. These
results are of the same order as for other works.7,24,25,44 Although
the maximum concentrations were relatively high, the median
values were between 20 and 60 ng L1, except for CLO with
a lower median.
– Compounds with intermediate concentrations in SW (SA,
IBU, and OZP), the maximum concentrations being up to 90 ng
L1. Although IBUwas found in only 3 samples, this is consistent
with the range of concentrations already found in French and
UK surface waters.21,24 The median values of these substances
were between 20 to 30 ng L1. OZP comes from directly ingested
OZP, as well as other anxiolytic drugs, such as nordiazepam and
diazepam.45
– 12 compounds with low concentrations, below LOQ or even
below LOD (ATE, FMQ, SFMZ, CBZ, COD, OFL, TRP,
MRP, NOR, WAR, CIP, CYCL). These compounds had
maximum concentrations less than 30 ng L1 and median values
up to 8 ng L1. Contrary to the results of this study, ATE had
previously been reported at concentrations of up to 240 ng
L1,3,7,30,48 and SFMZ had been found in the river Seine in France
in all samples with median concentrations up to 70 ng L1.10
Furthermore, CIP and CYCL were not detected in all SW
samples analysed in our study. It is surprising to note the absence
of CIP, the consumption of which is greater than that of OFL.34
HPCs concentrations in DW are shown in Fig. 2b, with the
same pattern as for SW (three groups of concentrations). In
general, there is a significant decrease in the concentrations of
most HPCs between SW andDW, which may be attributed to the
removal/degradation efficiency of the treatment processes. These
results are in accordance with the literature for the occurrence of
HPCs in DW (Table 1). Concentrations of HPCs found in DW
samples were around two to four times lower than their
maximum concentrations in SW (from 300 to 85 ng L1 for the
first group and from 30 to 12.5 ng L1 for the second group). The
HPCs ranking slightly changed between SW and DW samples.
However, the maximum concentration of SA was around 100 ng
L1 in both SW and DW and CAF and DMX had the higher
concentrations of HPCs in DW.
Two compounds were not found in the DW (MRP and SFMZ)
contrary to previous studies which have already reported
concentrations of SFMZ in DW.20,21 The nature of the treatment
processes used in the WUs may explain the difference of removal
of SFMZ between the previous studies and the present one. The
treatment scheme in all WUs investigated in this study presented
steps of clarification, oxidation (by ozone, chlorine or chlorine
dioxide), sand and activated carbon filtration, completed by an
ultimate disinfection step with chlorine or chlorine dioxide
(Table 3). Although in Vulliet et al.21 SFMZ was found at
0.8 ng L1 in one DW sample from a WU which used no
oxidation step besides only one single step of filtration before
disinfection with chlorine. Similarly, in Benotti et al.,20 SFMZ
was also found in DW at 3.0 ng L1. Sulfonamides are known to
be more reactive with chlorine or chlorine dioxide than with
chloramine.46,47 This may be the main reason which would
explain why SFMZ was entirely removed after disinfection by
chlorine or chlorine dioxide in this study and was found in DW
after disinfection with chloramine. Although COD, which
together with MRP, is a widely prescribed opioid analgesic, was
found in only one DW sample at only 1 ng L1, it has been
reported at 30 ng L1 in an other study.9 The WUs in the present
study all presented advanced oxidation processes with ozone for
which HPCs are well removed (Table 3). However, there was not
such treatment process in the WU investigated in Stackelberg
et al.9 to remove residual COD.
16 HPCs were found in both SW and DW samples. With the
exception of CYCL that was never detected, the other HPCs
were present in at least one sample (in SW or DW). Although
these results are globally comparable to other studies (Table 1)
some differences must be underlined, in particular for NSAIDs.
For example, ACE with a maximum in DW around 15 ng L1,
close to the 17 ng L1 already reported,21 has already been found
at a concentration of 210 ng L1 in France.24 In other countries,
reported concentrations for ACE varied from 8.5 ng L1 in
Finland,31,32 to 1350 ng L1 in USA.31
Antibiotics, CIP, NOR and OFL, have already been reported
in DW.19However, this may be the first report of FMQ inDW, at
low frequency and concentrations under 2 ng L1.
Therapeutic class distribution assessment
After considering the occurrence of each individual HPC in SW
and DW, it is interesting to show the global relative distribution
of HPCs with regard to their therapeutic class by summing the
concentrations and dividing by the number of substances per
class (Fig. 3). The total amount of HPCs, calculated as the sum
of the concentrations of the various classes, was greater than
10 mg L1 for SW, around ten times higher than for DW samples
(around 1.2 mg L1). The weight of each class was calculated as
This journal is ª The Royal Society of Chemistry 2011 J. Environ. Monit., 2011, 13, 2929–2939 | 2933
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Fig. 2 Individual HPCs concentrations in a) surface water, b) drinking water in north-west France. Box plots 25/75, line at median.
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a percentage, by dividing the global concentration of a class by
the total amount of HPCs.
Psychostimulants, CAF and its main metabolite, DMX, was
the main family with 48% in SW and 54% in DW. The ubiquitous
presence of CAF and DMX (resistant to waste and drinking-
water treatment processes) is consistent with previous
studies,24,49,50,51 some of which suggest considering CAF as
a possible marker of anthropogenic pollution.
Regarding the distribution of the remaining therapeutic classes
of HPCs in SW, (grey pie-chart in Fig. 3a), the top 5 are: 1)
NSAIDs and iodinated contrast media (ICM) (28%), 3) anxio-
lytic drugs (20%), 4) b-blockers (10%) and 5) lipid regulators
(8%). The distribution of other classes of less than 4% (and even
0% for antineoplastics that were not detected) can be explained
by the low administration dose, the partial excretion rates in
urine and natural attenuation (mainly through dilution,
biodegradation and photodegradation).34,36,52 A comparison
with consumption data shows that the NSAIDs ranking is
coherent, ACE being for example the most common drug
consumed in France in 2008.33,34 However, the results for anti-
biotics are not consistent with their consumption as exclusively
human drugs (CIP, OFL, NOR), or as both human and veteri-
nary drugs (SFMZ, TRP, FMQ).53,54 This result points out the
potential impact of the attenuation of antibiotics from their
release into the environment to natural waters. Fluo-
roquinolones and sulfonamides may be subject to sorption on
natural organic matter from sewage sludge, suspended matter in
water, soil and sediments.8,55–57 Antibiotics may also potentially
be transformed in the environment by direct or indirect photo-
lysis, and biodegradation.57,58
The difference in the weight of HPCs in SW and DW was
mainly for NSAIDs, being 28% in SW and 60% in DW, owing to
their resistance to DW treatment processes. The four other
therapeutic classes representing the major contribution of HPC
contamination in DW were lipid regulators and anxiolytic drugs,
ICM and b-blockers.
Drinking water treatment efficiency
The drinking water treatment efficiency was assessed using data
for 11 water treatment plants or water utilities (WUs) (WU 1 to
11, Table 3) for which SW and DW samples were analysed. The
removal efficiencies could only be calculated for samples less
than one day old. For WUs fed from several surface sources,
a weighted SW concentration was calculated from the feed flows
and the corresponding HPC data. The removal efficiency was
considered only if 3 results were available for a given HPC
(12 HPCs concerned, raw data presented in ESI†).
In parallel, the total organic carbon (TOC) was also measured
(Table 3) in the corresponding SW and DW samples, showing
a mean removal yield of 67% 16%.
The studied WUs used various processes for producing
drinking water, all of which included two types of treatment
(Table 3). The first group of processes was based on elimination
by retention, with clarification (coagulation, flocculation and
sedimentation), powder activated carbon (PAC) or granular
activated carbon (GAC) filtration, and sand filtration. The
second group included transformation by degradation processes
such as pre-, intermediate and post- oxidation with ozone O3
and/or chlorine, and disinfection by chlorination. The choice of
treatment processes for the WUs depends on the vulnerability of
the DW resources (surface water in rural areas).
Studying the retention/degradation rate of the 20 HPCs
through the 11 WUs of the study revealed four groups:
Table 3 Contents of total organic carbon in SW and DW samples from water utility 1 to water utility 11a
Water
utility (WU) Treatment processes
Type of
water samples Mean TOC /mg L1
TOC min–max
range /mg L1
WU 1 PAC/Cl2/C/H2O2–O3/Cl2 SW 5.9 4.2–9.3
DW 1.7 1.7
WU 2 Pre-O3/C/post-O3/GAC/ClO2 SW 3.3 4.8–1.8
DW – –
WU 3 Pre-O3/PAC-C/sand F/post-O3/GAC/Cl2 SW 3.0 3.0
DW 1.5 1.5
WU 4 Pre-Cl2/PAC/C/post-Cl2/sand F/O3/Cl2 SW 7.2 4.7–11.7
DW 1.7 1.6–1.7
WU 5 File 1 Pre-O3/C/O3/sand F/Cl2/GAC/Cl2 or ClO2 SW 3.6 1.9–5.2
File 2 Pre-O3/C/sand F/O3/GAC/Cl2 or ClO2 DW 2.0 2.0
WU 6 C, F, Cl2, O3 * SW 7.7 7.7
DW 1.9 1.9
WU 7 File 1 & 2: C/O3/sand F/post O3/GAC/Cl2 SW 3.3 3.0–3.5
File 3: C/O3/sand F/post O3/GAC/Cl2 DW 0.4 0.4
WU 8 C/sand F/post O3/GAC/Cl2 SW 3.2 3.0–3.3
DW 0.9 0.9
WU 9 Pre-O3/C/sand F/post-O3/GAC/Cl2 SW 3.3 3.3
DW 0.9 0.9
WU 10 Pre-O3/PAC-C/post-O3/C + GAC/sand F/Cl2 SW 5.4 5.4
DW 1.0 1.0
WU 11 Pre-O3/PAC-C/sand F/post-O3/GAC/Cl2 SW 2.9 2.6–3.2
DW 1.7 1.7
a C: Clarification, F: filtration, O3: ozonation, Cl2: chlorination (hypoclorite), ClO2: chorine dioxide, GAC: granular activated carbon, PAC: powdered
activated carbon, *(information about the nature of treatment processes are given despite their respective links between each other).
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– NOR, TRP,WAR, CBZ, IBU and COD seemed to be totally
removed;
– OZP, ATE, IOP, ACE, SA, CAF and DMX were partially
removed with efficiencies ranging from 70% for IOP to 96% for
DMX;
– CIP, FMQ and CLO were only present in DW at very low
concentrations;
– OFL, SFMZ, CYCL and MRP were not found in SW and
DW.
The average efficiency rate of HPC removal in the 11 WUs
was always greater than 90% with 6 between 90 and 95% and 5
greater than 95%. WU 4 (Table 3) with relatively high TOC
concentrations (up to 11.7 mg L1) has the lowest removal rate
(88%), average of 2 samplings.
These results must be treated with caution because some values
were eliminated (not validated) and, as samples were collected as
spot samples, the variability of the water quality over a period
was not taken into account.
Discussion
Saptial and temporal variations of HPCs
Urban area impact
The variation of HPCs load in the river Vilaine in two sites
located respectively upstream and downstream from the city of
Rennes (211 778 inhabitants in 2008) was studied in four SW
samples between February to April 2009. Fig. 4 represents the
loads difference between upstream and downstream for each the
three groups of HPCs defined above (Fig. 2). The loads differ-
ence was calculated in gram per day from the corresponding
mean flow rate of the river Vilaine at these two sites. As the river
mean flow strongly increased from 1.72 m3 s1 upstream versus
14.6 m3 s1 downstream, due to one tributary and the treated
wastewater discharge (360 000 inhabitants equivalents for the
WW treatment plant of Rennes area) the impact of dilution
appeared to be negligible with regard to the increase of
Fig. 3 Quantitative distribution of HPCs in a) surface water, b) drinking water.
Fig. 4 Load difference for the three groups of HPCs (g d1) between
upstream and downstream from Rennes.
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concentrations. These results may be explained by the high
release of HPCs in treated WW in spite of their partial elimina-
tion in treatment steps. Moreover, the close correlation between
the HPCs occurrence in SW and urban impact has already been
reported in the literature.2,6
Monthly variation
Mean HPCs concentrations of each group of HPCs determined
above (Fig. 2) varied over the fourmonths of the study, January to
April 2009 (Fig. 5). The same general tendency of monthly vari-
ations was observed for all three groups over the period excepted
for the group 3 between January to February 2009 for which the
low mean concentrations remained constant (i.e. 1.3 ng L1).
Mean concentrations of the group 1 to 3 of HPCs generally
decreased with a rate of 50%, 30% and 80% respectively, but less
than the mean flow rate (80%). Therefore, the general dissipation
of HPCs in SW over the investigated period cannot be explained
by the fact of dilution in this study. Otherwise, the greater
concentrations of HPCs observed in January and February may
be due to lower temperatures which may reduce both the
biodegradation and the photodegradation of HPCs in SW.32,59
Additionally, it may be assumed that the variations of drugs
prescription with time during the investigated period, which is
correlated to other factors besides the climatic conditions, could
also be responsible of the monthly variation observed of HPCs
contamination in SW.
However, a surprising increase of mean concentrations for all
HPCs groups was observed in March while the mean flow rate
decreased dramatically. This could be explained by a heavy
rainfall event at the beginning of the month (18.8 mm in Rennes
for the 3rd of March) with sewage overflows,60 contributing to
the increase of HPCs concentrations in river. In addition, the
possible effect of the weather instability during March (alter-
nating frosty days with relatively hot periods) on the occurrence
of human pathologies cannot be dismissed to understand these
results because it may contribute to increase drugs prescription.
However, the monthly variation results have to be treated with
caution because of the difference of the number of analysed
samples during each month, the number of SW sampled in
March 2009 being more than 2 to 5 times greater than during the
other 3 months (26 samples in March versus 8, 13 and 5 samples
in January, February and April, respectively).
DW treatments
The results presented above, in particular the treatment effi-
ciency, do not make it possible to assess the efficiency of each
treatment stage. However, the literature can provide some
answers. For example, the coagulation step does not seem to be
a suitable process for eliminating trace levels of HPCs.9,51,61,63
However, Stackelberg et al.9 showed moderate removal of SFMZ
(nearly 33%) and ACE (nearly 60%) after ferric chloride coagu-
lation. Adams et al.61suggested that antibiotics (seven sulfon-
amides and TRP) may be adsorbed onto suspended colloidal
matter in surface water, and may then be removed during
clarification.
For adsorption, activated carbon (in powder PAC or grain
GAC) is usually used to adsorb the natural organic matter and
micropollutants, depending on their Kow coefficient (octanol–
water partition coefficient). As organic compounds, such as IOP,
have a low Kow (<4) it is thought that they are poorly retained
on GAC or PAC.8,35
Sand–GAC filtration and PAC filtration are commonly used
in DW facilities to eliminate a wide range of fine particles
(colloids and supracolloids), bacteria and prevent odour and
taste in DW. This step can be very efficient with, for example,
more than 95% of CAF and CBZ removed.9 In addition, HPCs
may be biodegraded, for example during filtration on activated
carbon.64
Oxidation, with either ozone and/or chlorine, can lead to the
degradation of HPCs depending on oxidant doses, contact time,
pH, temperature conditions and on the structure and physical and
chemical properties of the HPCs. Adams et al.61 studied spiked
Missouri river water samples and distilled water (0.5 mg L1) with
7 antibiotics includingTRP, and found a 95%degradation of each
HPC (pH¼ 7.5, 0.3 mg L1O3, t¼ 1.3 min). Ternes et al.
63 found
more than 97%degradation forCBZ (pH¼ 7.8, 0.5mgL1O3, t¼
20 min), whereas CLO was poorly degraded (#40%) even under
high O3 concentration (2.5–3 mg L
1). ATE may be degraded by
ozone on its amine function50 and a complete SFMZ removal was
observed in 15 min with 0.4 g L1 ozone.65,66
Chlorination may also produce by-products with unexpected
properties. For example, chlorination of ATE could give three
by-products with potential phycotoxic activity.67 Moreover,
natural organic matter (NOM) may interfere during chlorination
with a reaction time varying from around 20 min in distilled
water up to 40 min in SW for a 90% degradation of antibiotics
with 0.1 mg L1 of Cl2.
61
Fig. 5 Monthly variations of HPCs concentration (group 1, 2, and 3) in
ng L1 in all SW samples between January to April 2009 (bars indicate the
standard deviation of mean HPCs concentrations).
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However, CAF and CBZ are neutral compounds and CLO
and IBU are acidic compounds and could resist chlorination.62
Chlorination for 200 to 300 min can lead to a 100% degradation
of SFMZ and ACE but only 8% and 20% of CAF and CBZ.9
All these findings are consistent with the results for the 11WUs
except for finding HPCs present at very low concentrations only
in DW (CIP, FMQ and CLO). Depending on the possible vari-
ability in all these treatment process parameters between all the
concerned WUs, the occurrence of CIP and FMQ in a few
samples may be explained. CLO, the metabolite of clofibrate,
was found in this study in SW and DW although clofibrate has
not been prescribed in France since 1999. However, its presence
in environment could be explained by its persistence in envi-
ronment and its resistance to chlorination. However, the author
observed some difficulties to differentiate CLO from its isomer
(mecoprop) which is used as a pesticide in this study area.68
Conclusions
The aim of this paper was to determine the occurrence of widely
used human pharmaceutical compounds and metabolites in the
surface water and drinking water in Brittany, France. The results
demonstrated the ubiquitous presence of 16 of the 20 target
HPCs in both surface water and drinking water, at concentra-
tions generally two or three times higher in surface water than in
treated water. Some high concentration can be stressed such as
300 ng L1 for acetaminophen in surface water and 100 ng L1 for
salicylic acid in treated water. Qualitatively, the evaluation of the
weighted distribution of HPCs in both surface water and treated
water showed that nearly half were psychostimulants (i.e.
caffeine and its main metabolite 1.7 dimethylxanthine), the other
half being mainly non steroidal anti-inflammatory drugs, iodin-
ated contrast media, anxiolytic drugs, lipid regulators and
b-blockers. Overall, comparing quantitative and qualitative
results with the assessment of the removal rate of HPCs for 11
selected WUs with a complete treatment, including clarification,
filtration, oxidation processes, the majority of HPCs seemed to
be well retained or degraded, by adsorption on activated carbon
and oxidation with ozone and/or chlorine. However, psychosti-
mulants and non steroidal anti-inflammatory drugs were not
completely removed.
In order to complete the results of this study, further experi-
ments could be carried out during extreme weather events, at
least during dry and wet periods, to study the possible effect on
water quality of DW resources of concentration at low water
level, or of soil leaching or dilution at high water level.
This study helps to provide an assessment, over a large area, of
the environmental footprint of HPC contamination from SW to
DW, suggesting the need for further research to prioritize HPCs
(i.e. resistent HPCs to DW treatment processes) and HPC by-
products to assess the health risk.
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